Deriving M-polynomial Based Topological Descriptors of Oral Antiviral Clinical Drug Nirmatrelvir

The novel human coronavirus known as SARS-CoV-2 poses a serious risk to human health. Regretfully, the US Food and Drug Administration (FDA) has approved very few oral antiviral medications for the treatment of COVID-19 patients. In the current study, we have explored the topological characterizatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Shibsankar Das, Modhuleena Mandal
Format: Article
Language:English
Published: Alexandru Ioan Cuza University of Iasi 2024-12-01
Series:Scientific Annals of Computer Science
Subjects:
Online Access:https://publications.info.uaic.ro/scientific-annals-of-computer-science/sacs-volumes/xxxiv-2/deriving-m-polynomial-based-topological-descriptors-of-oral-antiviral-clinical-drug-nirmatrelvir/
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The novel human coronavirus known as SARS-CoV-2 poses a serious risk to human health. Regretfully, the US Food and Drug Administration (FDA) has approved very few oral antiviral medications for the treatment of COVID-19 patients. In the current study, we have explored the topological characterization of the orally bio-available SARS Mpro inhibitor nirmatrelvir which in combination with ritonavir (under the brand name Paxlovid) is recently approved for emergency use authorization by FDA. Topological indices are a useful tool in chemical graph theory to determine the diverse pharmaceutical, biological and physico-chemical properties of a molecule. In this study, we ascertain several well-known degree-dependent topological indices for the medication nirmatrelvir directly using their common definitions in mathematics and alternatively by utilising M-polynomial after deriving M-polynomial of nirmatrelvir. In addition, we plot the obtained topological indices and the M-polynomial to comprehend the geometric behaviour of them. The outcomes can aid in the investigation of the physical characteristics of the recently created medications utilised to treat COVID-19.
ISSN:1843-8121
2248-2695